Skip to content
OpenCapital
Get started

Repligen RGEN Enterprise value

Enterprise value at other companies

TEC
Bio-TechneTECH
$8.26B-13.6%
Revvity logo
RevvityRVTY
$12.88B-13.7%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$222.48B+0.9%
Danaher logo
DanaherDHR
$148.16B-8.7%
Agilent Technologies logo
Agilent TechnologiesA
$34.39B+5.1%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$8B+4.2%

Other financials

Income statement

See full
Revenue$194.3M+14.8%
Gross profit$108.3M+18.5%
Operating income$15.9M+142%
Net income$8.3M+42.9%
EPS (diluted)$0.15+50.0%

Balance sheet

See full
Cash & equivalents$582.7M-16.4%
Total debt$687.6M+346%
Total equity$2.1B+6.0%
Total assets$2.9B+2.8%

Cash flow

See full
Operating cash flow$28.3M+88.6%
CapEx$4.7M+32.2%
Free cash flow$23.6M+106%

Valuation

See full
Market cap$7.45B-7.1%
P/E144.9×—
P/S10.1×-0.1×

Profitability

See full
Gross margin49.5%+2.7pp
Operating margin1.5%-14.0pp
Net margin17.1%-3.7pp
FCF margin21.2%+6.1pp

Returns & leverage

See full
Return on equity2.5%+1.9pp
Debt / equity0.3×+0.2×
Current ratio9.2×+2.4×

Where this comes from

Calculated from Repligen’s reported figures.

$6.6Bmarket cap+$687.6Mtotal debt−$582.7Mcash and equivalents=$6.74B

The official record: Repligen’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Repligen's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Repligen's enterprise value?
Repligen (RGEN) reported enterprise value of $6.74B in Q1 2026.
How has Repligen's enterprise value changed year-over-year?
Repligen's enterprise value increased by 2.1% year-over-year, from $6.6B to $6.74B.
What is the long-term trend for Repligen's enterprise value?
Over 5 years (2020 to 2025), Repligen's enterprise value has grown at a -1.2% compound annual growth rate (CAGR), from $9.91B to $9.35B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.